Cogent Biosciences Inc Investor Relations Material

Cogent Biosciences Inc. is a biotechnology company focused on the development of precision therapies for genetically defined diseases. The company's lead product, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting mutations in the KIT receptor tyrosine kinase. These mutations are critical in conditions such as systemic mastocytosis and advanced gastrointestinal stromal tumors. Cogent Biosciences holds a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.